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Degenerative cervical myelopathy [DCM] is a disabling and increasingly prevalent condition.
Variable reporting in interventional trials of study design and sample characteristics limits
the interpretation of pooled outcomes. This is pertinent in DCM where baseline characteris-
tics are known to influence outcome. The present study aims to assess the reporting of the
study design and baseline characteristics in DCM as the premise for the development of a
standardised reporting set.
Methods
A systematic review of MEDLINE and EMBASE databases, registered with PROSPERO
(CRD42015025497) was conducted in accordance with PRISMA guidelines. Full text arti-
cles in English, with >50 patients (prospective) or >200 patients (retrospective), reporting
outcomes of DCM were deemed to be eligible.
Results
A total of 108 studies involving 23,876 patients, conducted world-wide, were identified. 33
(31%) specified a clear primary objective. Study populations often included radiculopathy
(51, 47%) but excluded patients who had undergone previous surgery (42, 39%). Diagnosi-
tic criteria for myelopathy were often uncertain; MRI assessment was specified in only 67
(62%) of studies. Patient comorbidities were referenced by 37 (34%) studies. Symptom
duration was reported by 46 (43%) studies. Multivariate analysis was used to control for
baseline characteristics in 33 (31%) of studies.
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Conclusions
The reporting of study design and sample characteristics is variable. The development of a
consensus minimum dataset for (CODE-DCM) will facilitate future research synthesis in the
future.
Introduction
Chronic compression of the cervical spinal cord due to degenerative processes, including disc
herniation, spondylosis, and ligament hypertrophy or ossification, has been collectively
referred to as degenerative cervical myelopathy [DCM]. [1] Disability ranges from mild pain
to severe sensorimotor deficits including quadriplegia. DCM is estimated to be the most com-
mon spinal cord disorder, and is expected to have an increasing incidence with the aging pop-
ulation in the industrial world [2].
Presently, surgical decompression is the mainstay of treatment, although the type and tim-
ing of surgery remains controversial. Defining optimal treatment strategies has been challeng-
ing due to difficulties in research synthesis and the heterogeneous reporting of outcome
variables [3]. This is a recognized problem in many fields of healthcare and has led to the estab-
lishment of consensus-based, core outcome sets [4].
Effective pooled analysis and its accurate interpretation requires common outcome mea-
sures as well as an understanding of important study characteristics. This is particularly perti-
nent in DCM, where a number of baseline factors have been found to influence outcome [5,6].
Much like outcomes, these study components are often heterogeneous and not consistently
reported. Pioneered by organizations such as the National Institute of Neurological Disorders
[NIND], this has led to an extension of standardization from outcomes, to other study charac-
teristics [7]. The nomenclature for this is inconsistent and includes ‘common data elements’ or
‘minimum reporting sets’.
Various methods have been proposed for the development of a minimum reporting set.
One method is to map existing reporting practice by performing a systematic review of the lit-
erature. This information is then used to inform a DELPHI consensus process, that includes
relevant stakeholders such as clinicians, academics, allied care professionals, patients and care
givers. Organisations such as COMET [Core outcome measures in effectiveness trials] have
been setup to facilitate this process [8].
The benefit of collaborative study in DCM is recognized. For example, the systematic and
standardized approach of the AOSpine network has provided unique prospective datasets for
advancing our understanding of DCM [9–12]. These have the potential to accelerate the devel-
opment of optimal treatment for DCM, especially if future studies are designed on common
grounds, and supported by a minimum reporting set.
Our objectives therefore were to describe the reporting of baseline characteristics in studies
of DCM in order to inform a subsequent consensus process. This study complements and
extends existing work on ancillary outcome measures in DCM and is referred to as CODE-
DCM [Core outcomes and data elements in degenerative cervical myelopathy] [13,14].
Method
A systematic review was conducted in accordance with the PRISMA guidelines (S1 Table) and
registered with the PROSPERO (CRD42015025497) prospective register of systematic reviews.
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MEDLINE [Ovid] and Embase [Ovid] databases were searched on the 12th August 2015 using
the search strategy [“Cervical”] AND [“Myelopathy”] for articles focused on myelopathy sec-
ondary to chronic compression of the spinal cord. The search was conducted using the OVID
Basic Search function. Related search terms were not included. Animal studies, case reports
and letters/editorials were excluded.
Titles and abstracts were screened for relevance. Full text articles were subsequently
screened for eligibility according to the following criteria:
• English, full text
• Prospective study with >50 patients or retrospective study with >200 patients
• Assessment of clinical outcomes in response to a treatment strategy (conservative or
interventional)
• Articles published since 1st January 1995
Articles were screened by two authors [BMD, AE] and data were extracted independently
by two authors [BMD, MM] using a piloted proforma (S2 and S3 Tables). Discrepancies were
settled by discussion and mutual agreement. A retrospective review of prospectively collected
data was considered a prospective study.
Descriptive statistics were used to report frequency and proportion of measured data ele-
ments. Statistical comparisons were made using the Chi-Squared test, with significance set at
p = 0.05.
Results
The search strategy returned 6894 articles. Following application of inclusion and exclusion
criteria, 108 articles were considered [Fig 1]. There were 91 prospective studies and 17 rando-
mised controlled trials [RCT]. Further details about the shortlisted studies are available in our
previous publication [3]
Study design and patient selection
Of the 108 studies, 53 (49%) recorded whether ethical approval was obtained, including one
study which cited that it was not required. Overall study objectives were outlined in 103 (95%)
of studies; however, they were rarely specific. Thirty-three (31%) clearly specified a primary
objective, including the timing of outcome assessment and 36 (33%) included secondary objec-
tives. The investigation time period was specified in 93 (86%) studies and measured outcomes
were defined in 96 (89%).
Clear inclusion and exclusion criteria were described in 98 (91%) and 75 (69%) studies,
respectively. Patients who had previous cervical surgery were excluded by 42 (39%) studies.
The diagnostic criteria for myelopathy were often unclear, with MRI assessment specified in
only 67 (62%) studies. Neurophysiology for diagnosis was reported in two studies. Many stud-
ies included patients with myelopathy and radiculopathy; only 57 (53%) studies considered
myelopathy only patients. The frequency of causative pathology (e.g. Disc herniation, OPLL)
was specified in 87 (81%) of studies.
Patient characteristics
Most articles reported disease severity (97, 90%) using one or more functional assessment
tools, including the Japanese Orthopaedic Association assessment [JOA] (50, 46%), Nurick
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score (25, 23%), modified JOA (20, 19%) or the Oswestry Neck Disability Index [NDI] scales
(20, 19%).
Imaging, distinct to that required for assessment of radiological outcomes or diagnosis, was
reported by 59 (55%) studies. Typically this was MRI (58, 54%).
Imaging was used to report the disease level (46, 43%), number of treated levels (72, 67%)
or putative prognostic factors (28, 26%) such as cord signal change (22, 20%) or cord compres-
sion measures (18, 17%).
Patient age (107, 99%) and gender (105, 97%) were typically recorded in studies. Race was
recorded by 4 (4%) studies. General health status was referenced by 37 (34%) studies, typically
by reporting on study specific subcategories such as BMI (13, 12%), smoking status (23, 21%),
diabetes (9, 8%) or atherosclerotic disease (3, 3%). Only 9 studies used a recognized grading
system: ASA [American Society of Anesthesiologists] (4, 4%), CCI [Charlson Comorbidity
Fig 1. PRISMA flow diagram of search strategy.
doi:10.1371/journal.pone.0172564.g001
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Index] (3, 3%) or CIRS [Cumulative Illness Rating Scale] (1, 1%). Other, less frequently
reported patient information included employment status, workers compensation, mental
health and medication burden. Symptom duration was reported by 46 (43%) studies. Multivar-
iate analysis was used to control for baseline characteristics when evaluating outcomes, in 33
(31%) of studies.
Operative and post-operative course
The technical details of the intervention were detailed in 74 (69%) studies, two of which
reported the use of intraoperative electrophysiology. Follow-up timing was outlined by 74
(69%) studies. Mean follow-up was reported by 48 (44%) studies. Identification of the chosen
time points for outcome comparison was often ambiguous. Of the prospective studies, only 41
(45%) reported follow-up rates, or the data from which it could be calculated. Many studies
(19, 18%) used outcomes from ‘final follow up’ to assess their primary objectives.
Reporting differences between study designs
Reporting differences were noted when comparing prospective with retrospective studies, and
RCTs with other clinical trials (Table 1). When compared with retrospective studies, prospec-
tive studies were more likely to define the timing of follow up (p<0.01) and at which interval
endpoints would be compared (p = 0.04). When compared with all other clinical trials, RCTs
were more likely to define inclusion and exclusion criteria (p = 0.01) and follow up timing
(p = 0.05). However they were less likely to report symptom duration (p = 0.02) or the cause of
myelopathy (p<0.01) in their series. Reporting consistency did not therefore improve in all
domains with higher levels of study type.
Discussion
Summary of findings
Heterogeneity of reported study and sample characteristics exists in DCM clinical research,
even amongst studies of a higher level of evidence. This included study design characteristics,
such as the requirement for ethics, clearly defined objectives and inclusion/exclusion criteria
and population characteristics, such as general health status, symptom duration and disease
parameters (e.g. disease level and pathology subtype). The reporting of baseline severity whilst
prevalent, was reported with a variety of grading systems. This is not an unexpected finding,
given its prevalence in other fields [15] and in DCM outcome reporting [3]. However it
Table 1. Differences in reporting characteristics and study design. Significant results (p<0.05) are denoted by*.
Prospective Retrospective RCT Other Clinical
Trials
Ethics 43 47% 10 59% 0.38 9 53% 44 48% 0.73
Primary objective with time point 30 33% 3 18% 0.04* 4 24% 29 32% 0.84
Inclusion and exclusion criteria 63 69% 11 65% 0.71 16 94% 58 64% 0.01*
Cause of myelopathy specified 76 84% 11 65% 0.07 8 47% 79 87% <0.01*
Comorbidities 29 32% 8 47% 0.30 5 29% 32 35% 0.9
Comorbidity scoring system 3 3% 2 12% 0.13 0 0% 5 5% 0.32
Symptom duration 37 41% 9 53% 0.35 3 18% 43 47% 0.02*
Disease level(s) 38 42% 8 47% 0.69 10 59% 36 40% 0.14
Number of treated levels 60 66% 12 71% 0.67 12 71% 60 66% 0.1
Frequency of follow up 68 75% 6 35% <0.01* 15 88% 59 65% 0.05*
doi:10.1371/journal.pone.0172564.t001
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provides a challenge to effective pooled analysis [16] and interpretation of study results. As cer-
tain baseline characteristics of DCM patients are known to influence outcome[6], failure to
report these entails a risk of reporting bias.
Importance of reporting baseline characteristics
Reporting of baseline characteristics is important for the understanding of sample groups. It is
also fundamental for research synthesis, as these data elements indicate to what confidence
pooled outcomes can be trusted, e.g. whether patient selection was appropriate and for
appraisal of methodological quality [17,18].
A key aspect of this is preventing selection bias, defined by Cochrane as the “systematic dif-
ferences between study groups.” [17] Baseline data is required to make assessments of outcome
bias[19,20]. The variability identified in the present study, therefore poses a limitation in DCM
research, in particular:
1) Incomplete recording of baseline characteristics. A recent systematic review by
Tetreault et al (2015) considered prognostic factors in DCM [21]. The review identified excel-
lent evidence suggesting that symptom duration and baseline severity are important predictors
of outcomes; these factors were only reported by 46 (43%) and 97 (90%) of studies included in
this review. Similarly, age may impact outcome after surgery and was reported by 107 (99%) of
studies here. In addition other markers of general health status, such as diabetes, smoking and
psychological factors may also influence outcomes. This highlights not only the importance of
reporting such factors, but also perhaps a greater role for multivariate analysis, poorly used in
the studies we reviewed.
The recording of general health status is not straightforward, as on an individual basis, dis-
eases may be poorly represented for analysis whilst studies may focus on different co-morbidi-
ties, or use different grouping terms. Co-morbidity indexes are helpful tools to standardize
this, but the bundled data may obscure the significance of key individual predictors. The sig-
nificance of these indexes in DCM is not yet clearly defined.
2) Incomplete recording of symptoms. The overlap of treatments for compressive cervi-
cal myelopathy and radiculopathy, in addition to their possible coexistence, has lead to their
combined consideration in many studies. However, newer research indicates that the presence
of radiculopathy in non-myelopathic patients with imaging evidence of cord compression is
associated with higher risk of disease [22]. The impact of this on outcomes has not yet been
studied, but one would expect their disease profiles to differ [23], and as such, their commonly
unspecified combination is an obstacle for DCM pooled analysis. The distinction of radiculop-
athy from myelopathy can be difficult. This is an area in which electrophysiology could have a
significant role, yet it was only specified in two studies. Of note, one of these studies identified
electrophysiological markers of myelopathy severity [24] corroborated elsewhere [25].
3) Incomplete recording of the pathology type. DCM is a recently proposed umbrella
term to encompass cervical myelopathy due to cervical stenosis of degenerative aetiology [1].
Unification of the common clinical phenotype under a new index term will require future
studies to better clarify the types of pathologies included. In addition, if the field conformed
under such a term, it would lead to future, easy study identification. Whilst these ambitions
are helpful, it is important not to overlook that each pathology is distinct, particularly when
considered without myelopathy, and that their long-term disease profiles may differ.
Challenges for standardisation
The development of consensus derived reporting standards has helped homogenize reporting
and obviate many of the aforementioned limitations [7,26]. We intend to apply these processes
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to the field of DCM, to define the core outcomes and common data elements in degenerative
cervical myelopathy [CODE-DCM]. The results of this systematic review, alongside further
planned work, will be used to inform a DELPHI process, made up of key stakeholders includ-
ing patients, care givers, professionals and industry. This project has been registered with the
COMET initiative [14].
The challenge for CODE-DCM stakeholders when interpreting the findings of this system-
atic review will be to delineate variables present by convention or chance, from those that will
make a contribution. Gender for example is almost ubiquitously reported and not known to
influence outcome, whereas symptom duration is a significant predictor of outcome and was
reported by less than half of studies [27]. The selection of pertinent components is key to
ensure the resultant framework is concise and not an inflexible burden that could impede
novel research [4].
A threat to succinct guidelines would include attempts to future proof them. As already
mentioned, the ambiguity of co-morbidities is one example, but also the inclusion of promis-
ing new imaging techniques not captured in this systematic review, such as PET [28] and
Diffusion Tensor Imaging [29]. Future-proofing is extremely difficult and may risk overcom-
plicating reporting at this time. Instead, careful consideration of future research with subse-
quent updates may be more appropriate [4].
Further perspectives for DCM research
Some additional findings from this review are worth mentioning as they may represent knowl-
edge gaps in the field of DCM. The limited use of electrophysiology and the significance of
radiculomyelopathy compared with myelopathy on outcome improvements have already been
mentioned. An additional area of interest is the common exclusion of patients with previous
surgery. When assessing an intervention, it is understandable that potential confounders are
excluded, but given this group of patients represent a significant proportion of our practice, a
better understanding of their response to repeat surgery is a clinical need.
Limitations
This series reports on the articles selected by its search strategy, which has inherent limitations
addressed in our previous publication. [3]
An additional limitation distinct to the common data elements review compared to our
previous core outcomes review was a greater discrepancy between authors during data extrac-
tion. This likely relates to the requirement for many elements to be interpreted from the text
rather than simply copied. For example whether a study was prospective or retrospective was
not always recorded, and therefore on some occasions had to be interpreted from the method-
ology. This risks some errors in the reporting of findings. However, the use of two authors to
extract data, and the use of over 100 studies should prevent any such error impacting the over-
all findings. This observation would suggest a greater need for the use of reporting guidelines
such as STROBE and CONSORT [19,20].
Conclusion
Heterogeneity in the reporting of study and sample characteristics exists, even when consider-
ing higher levels of evidence. These findings echo those of outcome reporting in DCM, and
further exemplify the need for the establishment of a common reporting set [3].
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